A mutation in the second transmembrane region of the CB1 receptor selectively disrupts G protein signaling and prevents receptor internalization

Molecular Pharmacology

Volumn 56, Issue 3, 1999, Pages 611-618

  Roche, John P ^a   Bounds, Sid ^b   Brown, Sean ^a   Mackie, Ken ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b MDS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ASPARAGINE; ASPARTIC ACID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYCLIC AMP; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; POTASSIUM CHANNEL;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CALCIUM CURRENT; CELL COMMUNICATION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; INTERNALIZATION; MOUSE; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 0032819441     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.56.3.611     Document Type: Article

References (33)

1. Bean BP (1989) Neurotransmitter inhibition of neuronal calcium channels by changes in channel voltage dependence. Nature (Lond) 340:153-156.
2. Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M, Le Fur G and Casellas P (1995) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312:637-641.
3. Brodbeck RM, Sachais BS and Krause JE (1995) Residue 78 in the second transmembrane domain of the neurokinin-1 receptor is important in coupling high affinity agonist binding to multiple second messenger responses. Mol Pharmacol 47:1065-1071.
4. Chabre O, Conklin BR, Brandon S, Bourne HR and Limbird LE (1994) Coupling of the alpha 2A-adrenergic receptor to multiple G proteins. A simple approach for estimating receptor-G protein coupling efficiency in a transient expression system. J Biol Chem 269:5730-5734.
5. Chakrabarti S, Yang W, Law PY and Loh HH (1997) The mu-opioid receptor down-regulates differently from the delta-opioid receptor: Requirement of a high affinity receptor/G protein complex formation. Mol Pharmacol 52:105-113.
6. Chanda PK, Minchin MC, Davis AR, Greenberg L, Reilly Y, McGregor WH, Bhat R, Lubeck MD, Mizutani S and Hung PP (1993) Identification of residues important for ligand binding to the human 5-hydroxytryptamine1A serotonin receptor. Mol Pharmacol 43:516-520.
7. Chung FZ, Wang CD, Potter PC, Venter JC and Fraser CM (1988) Site-directed mutagenesis and continuous expression of human beta-adrenergic receptors. Identification of a conserved aspartate residue involved in agonist binding and receptor activation. J Biol Chem 263:4052-4055.
8. Daaka Y, Luttrell LM, Ann S, Della Rocca GJ, Ferguson SS, Caron MG and Lefkowitz RJ (1998) Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. J Biol Chem 273:685-688.
9. Garcia DE, Li B, Garcia-Ferreiro RE, Hernandez-Ochoa EO, Yan K, Gautam N, Catterall WA, Mackie K and Hille B (1998) G Protein beta-subunit specificity in the fast membrane-delimited inhibition of Ca2+ channels [In Process Citation]. J Neurosci 18:9163-9170.
10. Ho BY, Karschin A, Branchek T, Davidson N and Lester HA (1992) The role of conserved aspartate and serine residues in ligand binding and in function of the 5-HT1A receptor: A site-directed mutation study. FEBS Lett 312:259-262.
11. Horstman DA, Brandon S, Wilson AL, Guyer CA, Cragoe EJ Jr and Limbird LE (1990) An aspartate conserved among G protein receptors confers allosteric regulation of alpha 2-adrenergic receptors by sodium. J Biol Chem 265:21590-21595.
12. Howlett AC (1985) Cannabinoid inhibition of adenylate cyclase: Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 27:429-436.
13. i in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29:307-313.
14. Hsieh C, Brown S, Derleth C and Mackie (1999) Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem 73:493-501.
15. Jagerschmidt A, Guillaume N, Goudreau N, Maigret B and Roques BP (1995) Mutation of Asp100 in the second transmembrane domain of the cholecystokinin B receptor increases antagonist binding and reduces signal transduction. Mol Pharmacol 48:783-789.
16. Kong H, Raynor K, Yasuda K, Bell GI and Reisine T (1993) Mutation of an aspartate at residue 89 in somatostatin receptor subtype 2 prevents Na+ regulation of agonist binding but does not alter receptor-G protein association. Mol Pharmacol 44:380-384.
17. Lefkowitz RJ (1998) G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem 273: 18677-18680.
18. Mackie K, Lai Y, Westenbroek R and Mitchell R (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type voltage-dependent calcium currents in AtT-20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15:6552-6561.
19. Marchetti C, Carbonne E and Lux HD (1986) Effects of dopamine and noradrenaline on Ca2+ channels of cultured sensory and sympathetic neurons of chick. Pfluegers Arch 406:104-111.
20. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (Lond) 346:561-564.
21. Parent JL, Le Gouill C, Rola-Pleszczynski M and Stankova J (1996) Mutation of an aspartate at position 63 in the human platelet-activating factor receptor augments binding affinity but abolishes G protein-coupling and inositol phosphate production. Biochem Biophys Res Commun 219:968-975.
22. Pennefather PS, Heisler S and MacDonald JF (1988) A potassium conductance contributes to the action of somatostatin-14 to suppress ACTH secretion. Brain Res 444:436-450.
23. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180.
24. Savarese TM and Fraser CM (1992) In vitro mutagenesis and the search for structure-function relationships among G protein-coupled receptors. Biochem J 283:1-19.
25. Sealfon SC, Chi L, Ebersole BJ, Rodic V, Zhang D, Ballesteros JA and Weinstein H (1995) Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor. J Biol Chem 270:16683-16688.
26. Strader CD, Sigal IS, Register RB, Candelore MR, Rands E and Dixon RA (1987) Identification of residues required for ligand binding to the beta-adrenergic receptor. Proc Natl Acad Sci USA 84:4384-4388.
27. 2-adrenoreceptor that blocks coupling to potassium but not calcium channels. Science (Wash DC) 257:977-980.
28. Tao Q and Abood ME (1998) Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G protein coupling. J Pharmacol Exp Ther 286:651-658.
29. Twitchell W, Brown S and Mackie K (1997) Cannabinoids inhibit N-and P/Q-type calcium currents in cultured rat hippocampal neurons. J. Neurophysiol 78:43-50.
30. Wang CD, Buck MA and Fraser CM (1991) Site-directed mutagenesis of alpha 2A-adrenergic receptors: Identification of amino acids involved in ligand binding and receptor activation by agonists. Mol Pharmacol 40:168-179.
31. Yan K and Gautam N (1997) Structural determinants for interaction with three different effectors on the G protein beta subunit. J Biol Chem 272:2056-2059.
32. Zhang J, Ferguson SS, Barak LS, Aber MJ, Giros B, Lefkowitz RJ and Caron MG (1997) Molecular mechanisms of G protein-coupled receptor signaling: Role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization. Receptors Channels 5:193-199.
33. Zhou W, Flanagan C, Ballesteros JA, Konvicka K, Davidson JS, Weinstein H, Millar RP and Sealfon SC (1994) A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. Mol Pharmacol 45: 165-170.